| Evidence review: prevention and management of neutropenic sepsis in cancer patients |
|-------------------------------------------------------------------------------------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

Chayakulkeeree 2003

| Clinical features and settings | Adult or adolescent patients (>12 years) with febrile (>38°C) neutropenic (<0.5X10 ⁹ /L) episodes admitted to a single hospital between 1999 and 2000. |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Participants | 267 episodes (220 patients). 158/220 (72%) had haematological malignancy. Mean age was 44.7 years. Episodes were clinically documented infection 38/267, microbiologically documented infection 90/267 and fever of unknown origin 139/267 |

| Study design | Retrospective case series. Consecutive sample. Thailand. |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Target condition and reference standard(s) | Favourable outcome: fever resolved in 5 days of starting treatment and without complications |
| | Unfavourable outcome: Death, serious complications, modification of initial therapy, relapse of resolved fever or fever longer than 5 days. |
| | Reference standard was clinical follow up reported in medical records. |
| ndex and comparator | Lab tests (unclear exactly when they were done) |
| tests | Haemoglobin < 8g/dl |
| | Creatinine ≥ 2 mg/dl |
| | Sodium ≥ 150 mmol/L |
| | Potassium < 3.5 mmol/L |
| | Bicarbonate < 24 mmol/L |
| | Alanine transaminase ≥ 74 U/L |
| | Aspartate transaminase ≥ 80 U/L |
| | Alkaline phosphatase ≥ 117 U/L |
| | Bilirubin ≥ 2mg/sl |
| | Albumin <2.5 mg/dl |
| | Globulin ≥ 3.5 mg/dl |
| | Chest X-ray |
| | Median values of full blood count in the two groups (favourable versus unfavourable) were also reported. |
| Follow-up | The outcome definition mentions 5 days , unclear whether deaths or serious complications outside this period were included. |
| Notes | |